Immunic gets a "positive surprise" from lead asset trialApril 13, 2023 at 08:00 AM EDT
Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC). Vitt describes it as "wonderful data" that came as a "positive surprise." Contact DetailsProactive United States Proactive United States +1 347-449-0879 More NewsView More
Rocket Lab Stock Jumps After Earnings, Despite Neutron Delay
Today 10:32 EST
Occidental Petroleum is a Buy in Q4 2025
Today 9:22 EST
Amazon Is One of the Clearest Buys If the Market Dips Again
Today 7:06 EST
CoreWeave's Guidance Cut: A Buying Opportunity in Disguise?
November 11, 2025
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|
